Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.38 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19655507 | 0.86 | ANPEP (0.41) | ANPEP | |
| SCHEMBL20997046 | 0.84 | PARP14 (0.41) | NOTUMANPEPPARP14 | |
| SCHEMBL24334472 | 0.83 | ANPEP (0.40) | ANPEPPARP14 | |
| SCHEMBL24256389 | 0.78 | NOTUM (0.47) | NOTUMNPSR1ALOX15ANPEP | |
| SCHEMBL16579400 | 0.78 | NOTUM (0.52) | NOTUMNPSR1ALOX15SETDB1 | |
| SCHEMBL27048554 | 0.78 | CCNE1 (0.35) | — | |
| SCHEMBL22917093 | 0.78 | PARP14 (0.46) | NPSR1ANPEPPARP14 | |
| SCHEMBL24968449 | 0.78 | NOTUM (0.44) | NOTUMNPSR1ALOX15PARP14 | |
| SCHEMBL14262407 | 0.78 | CYP19A1 (0.36) | ANPEP | |
| SCHEMBL26318734 | 0.77 | NOTUM (0.46) | NOTUMNPSR1ALOX15SETDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022272133-A2 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220118120-A1 | CANCER DIAGNOSTIC IMAGING AGENTS | Technische Universität München (DE) | 2022-04-21 | — | — | US | disclosed |
| WO-2020006423-A9 | SYNTHETIC GUIDE MOLECULES, COMPOSITIONS AND METHODS RELATING THERETO | EDITAS MEDICINE, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118120-A1 | CANCER DIAGNOSTIC IMAGING AGENTS | FOLH1, FOLR1, KLK3 | NOTUM 4501/4885NPSR1 865/4885ALOX15 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.